[Music] Hi, I'm Lizzie. I'm a developer advocate at Cloudflare. And I'm Nick. I'm a developer experience engineer at work OS. Yes. So, at Cloudflare, I make a lot of AI demos, AI MCP servers. Anyone here also making any of those? Yes. Agents. Nice. Of course, should have guessed because conference. So, I've been having fun making agents and MCP servers that act on behalf of me. I built an agent to auto vote in the NBA finals for me and then I got blocked eventually. Uh, anyways, like book tennis courts in S ...

MongoDB Atlas for Government already provides a flexible way for the U.S. public sector to deploy, run, and scale modern applications in the cloud within a dedicated environment built for FedRAMP Moderate workloads. Achieving FedRAMP High and IL5 will allow MongoDB Atlas for Government's secure, reliable, and high-performance modern database solutions to be used to manage high-impact data, such as in emergency services, law enforcement systems, financial systems, health systems, and any other system where l ...

[Music] Thank you everyone for coming here. I hope you're uh excited to figure out with me what enterprise ready MCP means. Uh I'm not sure a month ago people even fully understood what MCP meant.Um so we're all on this journey together. Um, but hopefully it should be fun. So, I was chatting to a good friend and colleague who is is giving a talk tomorrow on building MCP servers and what it looks like to build that out.And his question was, how do the tools of today map to the AI systems of tomorrow. We alre ...

InnovationRx: Health Insurers Vow To Improve Prior Authorization (Again) https://t.co/GMn8UokZEc https://t.co/2NHGOdIkNI ...

Key Takeaways WYY dropped 43.5% in a month after missing Q1 estimates and posting a $2.7M accounting adjustment. Delayed customer payments cut cash to $3.7M, raising short-term liquidity concerns for WidePoint. WidePoint secured 3 task orders under the $2.7B Spiral 4 contract, with more expected in H2 2025.Shares of WidePoint Corporation (WYY) have declined 43.5% over the past month compared against the Zacks Computer - Services industry’s rise of 0.6%. The stock has underperformed the Zacks Computer and ...

IceCure Medical (ICCM) Q1 2025 Earnings Call May 28, 2025 10:00 AM ET Speaker0 Good morning and thank you for standing by. Currently, all the participants are in a listen only mode. After management's discussion, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Michael Poliview. Please go ahead. Speaker1 Thank you, Ioanni, and welcome to iSecure Medical's conference call to review the financial results a ...

Federal certification affirms that Varonis’ unified platform meets rigorous cloud security requirements mandated by U.S. federal agenciesMIAMI, May 19, 2025 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, proudly announces that its cloud-native Data Security Platform is the first in its category to achieve Federal Risk and Authorization Management Program (FedRAMP®) Authorization. The industry milestone confirms that Varonis’ AI-driven platform aligns with rigorous sta ...

MONTRÉAL, May 12, 2025 (GLOBE NEWSWIRE) -- Falco Resources Ltd. (TSX.V: FPC) ("Falco" or the "Corporation") is pleased to announce that it has responded to all questions and comments requested by the Direction de l'évaluation environnementale ("DEE") des projets industriels et miniers on February 27, 2025 (the "Correspondence"), as more fully described in Falco's press release dated March 3, 2025. The responses, commitments, and explanatory letter submitted (the "Responses") follow the meetings and clarific ...

Press Release CROSSJECT provides updates on the EUA filing of ZEPIZURE® CROSSJECT and its EUROFINS CDMO partner successfully completed the aseptic filling of all ZEPIZURE® registration batches and anticipate the delivery of the last manufacturing data needed for U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) submission in June 2025.CROSSJECT started the final regulatory activities for the ZEPIZURE® dossier submission under EUA.CROSSJECT began manufacturing EUA batches, intended as ...

Core Points - Pharma Equity Group A/S held its Annual General Meeting on April 16, 2025, where various proposals were discussed and adopted [1][6] Group 1: Board of Directors' Report - The former CEO, Thomas Kaas Selsø, presented the Board's report on the Company's activities over the past year, addressing shareholder questions regarding the Market Maker agreement with Danske Bank and the potential delisting from Nasdaq Copenhagen [3][4] - Shareholders expressed concerns about the declining share price, attributing it to large shareholders selling their shares, while also acknowledging the Company's successful financing in 2024 and positive research results [4][5] Group 2: Financial Proposals - The audited 2023 annual report was presented, and the discharge of the Board and Executive Management was proposed, with no objections raised from shareholders [8][11] - The expected revenue for the current financial year was projected at DKK 11 million, based on valuations prepared by Baker Tilly and reviewed by Danske Bank [9] - Outstanding convertible loans were confirmed to total approximately DKK 13 million [10] Group 3: Remuneration and Board Elections - The remuneration for the Board of Directors for the 2025 financial year was proposed, with the Chairman receiving DKK 350,000 and Board members receiving DKK 150,000 [14] - All current Board members were re-elected, and two new members, Troels Peter Troelsen and Charlotte Pahl, were elected [16][17] - BDO Statsautoriseret Revisionsaktieselskab was re-elected as the Company's auditor [18] Group 4: Proposals and Authorizations - Three proposals from the Board were discussed, requiring different majorities for adoption, and all were approved without objections [19][20] - The chairman was authorized to file the adopted resolutions with the Danish Business Authority [21] Group 5: Company Overview - Pharma Equity Group A/S is dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S, with a focus on healthcare and innovative medical solutions [23][24]